Element Biosciences Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
449
- Latest Deal Type
-
Series E
- Investors
-
15
Element Biosciences General Information
Description
Developer of genetic analysis tools designed to be used for the research and diagnostic markets. The company's technology develops a modular and high-performing DNA sequencing platform that will deliver quality data and workflow flexibility and make next-generation sequencing technology more accessible, enabling medical researchers to benefit from and improve their research.
Contact Information
Website
www.elementbiosciences.comCorporate Office
- 10055 Barnes Canyon Road
- Suite 100
- San Diego, CA 92121
- United States
Corporate Office
- 10055 Barnes Canyon Road
- Suite 100
- San Diego, CA 92121
- United States
Element Biosciences Timeline
Element Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series E) | 09-Jun-2026 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series D) | 11-Jul-2024 | Completed | Generating Revenue | |||
| 5. Accelerator/Incubator | 23-Mar-2023 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series C) | 29-Jun-2021 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series B) | 26-Jun-2020 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 18-Jun-2019 | $15M | $20M | Completed | Stealth | |
| 1. Seed Round | 11-Sep-2017 | $5M | $5M | Completed | Stealth |
Element Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series D-1 | ||||||||
| Series C | ||||||||
| Series B | ||||||||
| Series A | 8,299,215 | $0.000100 | $0.11 | $1.81 | $1.81 | 1x | $1.81 | 6.23% |
| Seed | 8,865,115 | $0.000100 | $0.03 | $0.58 | $0.58 | 1x | $0.58 | 6.66% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Element Biosciences Comparisons
Industry
Financing
Details
Element Biosciences Competitors (27)
One of Element Biosciences’s 27 competitors is InterpretOmics, a Formerly VC-backed company based in Bangalore, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| InterpretOmics | Formerly VC-backed | Bangalore, India | ||||
| DNAnexus | Venture Capital-Backed | San Francisco, CA | ||||
| Qlucore | Formerly VC-backed | Lund, Sweden | ||||
| Illumina | Formerly VC-backed | San Diego, CA | ||||
| Oxford Nanopore Technologies | Formerly VC-backed | Oxford, United Kingdom |
Element Biosciences Patents
Element Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026217901-A1 | Compositions for fluorescence resonance energy transfer in high throughput sequencing | Pending | 11-Apr-2025 | ||
| WO-2026207503-A1 | Sequencing systems | Pending | 27-Mar-2025 | ||
| WO-2026198648-A2 | Cell-based display polypeptides and methods of use thereof | Pending | 18-Mar-2025 | ||
| WO-2026198648-A3 | Cell-based display polypeptides and methods of use thereof | Pending | 18-Mar-2025 | ||
| WO-2026192958-A1 | Base calling in next generation sequencing analysis | Pending | 10-Mar-2025 | G06V20/693 |
Element Biosciences Signals
Element Biosciences Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Samsung Electronics | Corporation | Minority | ||
| Wellington Management | Asset Manager | Minority | ||
| CONNECT (San Diego) | Accelerator/Incubator | |||
| Counterpoint Global | Asset Manager | Minority | ||
| Janus Henderson Investors | Asset Manager | Minority |
Element Biosciences Acquisitions (1)
Element Biosciences’s most recent deal was a Merger/Acquisition with Loop Genomics. The deal was made on 08-Feb-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Loop Genomics | 08-Feb-2022 | Merger/Acquisition | Medical Supplies |
Element Biosciences FAQs
-
When was Element Biosciences founded?
Element Biosciences was founded in 2017.
-
Where is Element Biosciences headquartered?
Element Biosciences is headquartered in San Diego, CA.
-
What is the size of Element Biosciences?
Element Biosciences has 449 total employees.
-
What industry is Element Biosciences in?
Element Biosciences’s primary industry is Diagnostic Equipment.
-
Is Element Biosciences a private or public company?
Element Biosciences is a Private company.
-
What is Element Biosciences’s current revenue?
The current revenue for Element Biosciences is .
-
How much funding has Element Biosciences raised over time?
Element Biosciences has raised $683M.
-
Who are Element Biosciences’s investors?
Samsung Electronics, Wellington Management, CONNECT (San Diego), Counterpoint Global, and Janus Henderson Investors are 5 of 15 investors who have invested in Element Biosciences.
-
Who are Element Biosciences’s competitors?
InterpretOmics, DNAnexus, Qlucore, Illumina, and Oxford Nanopore Technologies are some of the 27 competitors of Element Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process